Risk of Second Cancers in Merkel Cell Carcinoma: A Meta-Analysis of Population Based Cohort Studies

Table 2

Risk estimates individual second malignancies occurring after one year of MCC diagnosis.

Study, year	Colon cancer	Breast cancer	Lung cancer	NHL	CLL	Malignant melanoma
Howard et al., 2006 [25]	1.48; (0.76–2.58)	0.83; (0.30–1.81)	1.14; (0.61–1.95)	1.65; (0.53–3.85)	1.18; (0.02–6.56)	1.39; (0.28–4.07)
Koljonen et al., 2010 [26]	3.33; (0.40–12.0)	1.43; (0.04–7.95)	—	—	19.7; (0.50–109)	—
Bzhalava et al., 2011 [27]	0.63; (0.26–1.53)	1.02; (0.42–2.45)	1.21; (0.5–2.91)	0.7; (0.1–4.97)	—	3.58; (1.49–8.6)
Youlden et al., 2014 [28]	1.83; (1.21–2.67)	1.76; (0.64–3.82)	1.71; (0.82–3.14)	2.19; (0.60–5.61)	0.00; (0.00–3.83)	3.31; (1.89–5.37)

NHL: non-Hodgkin’s lymphoma; CLL: chronic lymphocytic lymphoma.